Literature DB >> 10734005

Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors.

G Fénelon1, F Mahieux, R Huon, M Ziégler.   

Abstract

Hallucinations, mainly of a visual nature, are considered to affect about one-quarter of patients with Parkinson's disease. They are commonly viewed as a side-effect of antiparkinsonian treatment, but other factors may be involved. The aim of this study was to determine the phenomenology, prevalence and risk factors of hallucinations in Parkinson's disease. Two-hundred and sixteen consecutive patients fulfilling clinical criteria for Parkinson's disease were studied. Demographic and clinical variables were recorded, including motor and cognitive status, depressive symptoms and sleep-wake disturbances. Patients with and without hallucinations were compared using non-parametric tests, and logistic regression was applied to significant data. Hallucinations had been present during the previous 3 months in 39.8% of the patients, and fell into three categories: minor forms, consisting of a sensation of a presence (person), a sideways passage (commonly of an animal) or illusions were present in 25.5% of the patients (an isolated occurrence in 14.3%), formed visual hallucinations were present in 22.2% (isolated in 9.3%) and auditory hallucinations were present in 9.7% (isolated in 2.3%). Patients with minor hallucinations had a higher depression score than non-hallucinators but did not differ in other respects. Logistic regression analysis identified three factors independently predictive of formed visual hallucinations: severe cognitive disorders, daytime somnolence and a long duration of Parkinson's disease. These findings indicate that, when minor hallucinations are included, the total prevalence is much higher than previously reported. A simple side-effect of dopaminergic treatment is not sufficient to explain the occurrence of all visual hallucinations. The main risk factor in treated patients is cognitive impairment, although sleep-wake cycle disturbances, and possibly other factors related to the duration of the disease, act as cofactors.

Entities:  

Mesh:

Year:  2000        PMID: 10734005     DOI: 10.1093/brain/123.4.733

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  150 in total

Review 1.  An update expert opinion on management and research strategies in Parkinson's disease psychosis.

Authors:  Jennifer G Goldman; Christina L Vaughan; Christopher G Goetz
Journal:  Expert Opin Pharmacother       Date:  2011-06-02       Impact factor: 3.889

2.  The changing face of Parkinson's disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria.

Authors:  Gilles Fénelon; Thierry Soulas; Franck Zenasni; Laurent Cleret de Langavant
Journal:  Mov Disord       Date:  2010-04-30       Impact factor: 10.338

3.  Visual search in Dementia with Lewy Bodies and Alzheimer's disease.

Authors:  Kelly M Landy; David P Salmon; J Vincent Filoteo; William C Heindel; Douglas Galasko; Joanne M Hamilton
Journal:  Cortex       Date:  2015-09-21       Impact factor: 4.027

Review 4.  Dopamine D3 receptor: A neglected participant in Parkinson Disease pathogenesis and treatment?

Authors:  Pengfei Yang; Joel S Perlmutter; Tammie L S Benzinger; John C Morris; Jinbin Xu
Journal:  Ageing Res Rev       Date:  2019-11-22       Impact factor: 10.895

5.  Parkinsonism with excessive daytime sleepiness--a narcolepsy-like disorder?

Authors:  Christian Baumann; Luigi Ferini-Strambi; Daniel Waldvogel; Esther Werth; Claudio Lino Bassetti
Journal:  J Neurol       Date:  2005-02       Impact factor: 4.849

6.  Effect of visual cues on the resolution of perceptual ambiguity in Parkinson's disease and normal aging.

Authors:  Mirella Díaz-Santos; Bo Cao; Samantha A Mauro; Arash Yazdanbakhsh; Sandy Neargarder; Alice Cronin-Golomb
Journal:  J Int Neuropsychol Soc       Date:  2015-03-13       Impact factor: 2.892

7.  Psychometric Properties and Characteristics of the North-East Visual Hallucinations Interview in Parkinson's Disease.

Authors:  Kelsey A Holiday; Eva Pirogovsky-Turk; Vanessa L Malcarne; J Vincent Filoteo; Irene Litvan; Stephanie L Lessig; David Song; Dawn M Schiehser
Journal:  Mov Disord Clin Pract       Date:  2017-03-16

Review 8.  Pathophysiology and treatment of psychosis in Parkinson's disease: a review.

Authors:  Laura B Zahodne; Hubert H Fernandez
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

9.  Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.

Authors:  Herbert Y Meltzer; Roger Mills; Stephen Revell; Hilde Williams; Ann Johnson; Daun Bahr; Joseph H Friedman
Journal:  Neuropsychopharmacology       Date:  2009-11-11       Impact factor: 7.853

Review 10.  Psychiatric aspects of Parkinson's disease--an update.

Authors:  Anette Schrag
Journal:  J Neurol       Date:  2004-07       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.